Education
About Us
Working with TipRanks
Follow Us
Profound Medical (TSE:PRN)
TSX:PRN
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.49Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted several strong positives — 43% YoY revenue growth, growing install base and pipeline, favorable Medicare reimbursement shifts, imminent Level‑1 CAPTAIN data readout, a quantified path to profitability (~$85M revenue target with 70%+ gross margins), and improving cash burn with $59.7M cash on hand. Offsetting these are a widened Q4 net loss, modest gross margin compression driven by product mix and international introductory pricing, high operating expenses, near‑term capital/recurring revenue mix volatility, and current utilization per site below the company’s modeled targets. Taken together, the positives (notably clinical validation, reimbursement tailwinds, pipeline growth and a clear profitability plan) outweigh the near‑term financial and execution challenges.Company Guidance
Strong Revenue Growth
Q4 2025 revenue of $6.0M, up 43% year-over-year from $4.2M; recurring revenue of $2.3M and one-time capital sales of $3.7M.
Growing Installed Base and Pipeline
78 TULSA‑PRO sites at year-end 2025 with a qualified sales pipeline cited at ~110 systems (up from 97 in prior reference); company expects ~120 installs by end of 2026 and is targeting a 200-site installed base.
Clinical Milestone — CAPTAIN Readout
CAPTAIN randomized multicenter trial completed enrollment; 6‑month primary safety and QoL endpoints and 90‑day perioperative data to be presented at EAU (mid‑March), positioning TULSA as a Level 1 comparative trial versus robotic prostatectomy.
Improved Reimbursement Environment
CMS/Medicare reimbursements favor iMRI procedures: 2026 Medicare national average for TULSA procedure $13,479 (vs $10,860 robotic surgery and $9,672 focal therapies); in‑bore MR biopsy reimbursement set at ~$5,500 vs ~$3,500 for MR‑registered ultrasound (≈57% higher).
Path to Profitable Growth Quantified
Management math: 200 TULSA sites × 50 procedures/site × $5,500 per procedure → $55M procedural revenue + $10M service + ~$20M capital sales (~40 systems × $500k) → ≈$85M revenue and profitability assuming 70%+ gross margins.
Recurring Revenue Model and Per‑Procedure Pricing
Reported fixed disposable price of $5,500 per TULSA procedure; management reiterates long‑term thesis that majority of revenue will be recurring (target >70% recurring long term).
BPH Module & TAM Expansion
New TULSA‑AI volume‑reduction module reduces procedure times to ~60–90 minutes, enabling stacked TULSA days and management claims potential to add ~400,000 patients to annual TAM (tripling prior TAM).
Sonalleve Platform Progress
Sonalleve: ~10 devices operational internationally; >4,000 women treated for adenomyosis/fibroids; pursuing FDA strategy and potential recurring revenue opportunities beyond capital sales.
Improving Cash Burn Trend and Cash Balance
Cash of $59.7M as of Dec 31, 2025; quarterly cash burn trend showed reduction from ~ $10M/quarter (first half) to ~ $8M (Q3) and under ~$6.5M (Q4), indicating movement toward lower burn and eventual cash flow positivity.
TSE:PRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:PRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | C$10.00 | C$7.08 | -29.20% |
Nov 13, 2025 | C$9.04 | C$9.42 | +4.20% |
Aug 14, 2025 | C$7.54 | C$5.96 | -20.95% |
May 08, 2025 | C$6.90 | C$6.42 | -6.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Profound Medical (TSE:PRN) report earnings?
Profound Medical (TSE:PRN) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Profound Medical (TSE:PRN) earnings time?
Profound Medical (TSE:PRN) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:PRN EPS forecast?
TSE:PRN EPS forecast for the fiscal quarter 2026 (Q1) is -0.32.